Verition Fund Management
CERE

Verition Fund Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Verition Fund Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-204,808
Closed -$8.37M – 3597
2024
Q2 		$8.37M Buy
204,808
+71,985
+54% +$3M 0.05% 438
2024
Q1 		$5.61M Buy
132,823
+52,823
+66% +$2.22M 0.04% 597
2023
Q4 		$3.39M Buy
+80,000
New +$2.3M 0.03% 597
2022
Q4 		– Sell
-19,457
Closed -$550K – 2915
2022
Q3 		$550K Buy
+19,457
New +$579K 0.01% 1830
2022
Q2 		– Sell
-82,135
Closed -$2.88M – 3197
2022
Q1 		$2.88M Buy
+82,135
New +$2.4M 0.03% 713
2021
Q3 		– Sell
-37,528
Closed -$961K – 2387
2021
Q2 		$961K Sell
37,528
-223,976
-86% -$3.21M 0.01% 822
2021
Q1 		$3.59M Buy
261,504
+226,074
+638% +$3.31M 0.04% 265
2020
Q4 		$587K Buy
35,430
+5,929
+20% +$77K 0.01% 628
2020
Q3 		$308K Buy
+29,501
New +$311K 0.01% 771

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Verition Fund Management's CERE Position: Q3 2024 in Review

Verition Fund Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 204,808 shares — an estimated $8.37M sold.

Verition Fund Management first reported a position in CERE in Q3 2020 and held it in 9 quarters. The position peaked at $8.37M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Verition Fund Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 204,808 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $8.37M.
  • Verition Fund Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • Verition Fund Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $8.37M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.